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Abstract
Background: Identification of predictive markers of response to treatment is a major objective in breast cancer.
A major problem in clinical sampling is the variability of RNA templates, requiring accurate management of tumour
material and subsequent analyses for future translation in clinical practice. Our aim was to establish the feasibility
and reliability of high throughput RNA analysis in a prospective trial.
Methods: This study was conducted on RNA from initial biopsies, in a prospective trial of neoadjuvant chemotherapy
in 327 patients with inoperable breast cancer. Four independent centres included patients and samples. Human U133
GeneChips plus 2.0 arrays for transcriptome analysis and quantitative RT-qPCR of 45 target genes and 6 reference genes
were analysed on total RNA.
Results: Thirty seven samples were excluded because i) they contained less than 30% malignant cells, or ii) they
provided RNA Integrity Number (RIN) of poor quality. Among the 290 remaining cases, taking into account strict
quality control criteria initially defined to ensure good quality of sampling, 78% and 82% samples were eligible for
transcriptome and RT-qPCR analyses, respectively. For RT-qPCR, efficiency was corrected by using standard curves
for each gene and each plate. It was greater than 90% for all genes. Clustering analysis highlighted relevant breast
cancer phenotypes for both techniques (ER+, PR+, HER2+, triple negative). Interestingly, clustering on trancriptome
data also demonstrated a “centre effect”, probably due to the sampling or extraction methods used in on of the
centres. Conversely, the calibration of RT-qPCR analysis led to the centre effect withdrawing, allowing multicentre
analysis of gene transcripts with high accuracy.
Conclusions: Our data showed that strict quality criteria for RNA integrity assessment and well calibrated and
standardized RT-qPCR allows multicentre analysis of genes transcripts with high accuracy in the clinical context.
More stringent criteria are needed for transcriptome analysis for clinical applications.
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Breast cancer is a clinically and biologically heteroge-
neous disease. Most breast cancer patients in whom pri-
mary systemic therapy is proposed are treated with
anthracycline- and/or taxane-based regimens. However,
no clearly validated predictive or prognostic factors are
available to determine the best regimen to obtain a
pathological complete response and improve survival in
patients with breast carcinoma. Neoadjuvant chemother-
apy is associated with the same survival benefits as adju-
vant chemotherapy with increased breast-conserving
surgery rates [1,2]. Furthermore, neoadjuvant che-
motherapy represents an opportunity to correlate mole-
cular variables in the initial biopsy with treatment
response and to explore mechanisms of drug resistance.
Identification of predictive markers of individual
response to chemotherapy is a major challenge to
ensure optimal treatment for patients. Microarray and
quantitative reverse transcription polymerase chain reac-
tion (RT-qPCR) technologies are complementary power-
ful tools to define gene expression profiles in breast
carcinoma. However, further work is required to move
these tools from research laboratories to clinical prac-
tice, mainly by improving standardization of the process
and management of samples and derived material before
analysis.
The neoadjuvant chemotherapy REMAGUS 02 (RO2,
ISRCTN 10059974) [3] was designed to assess anti-
tumor activity of sequential epirubicin/cyclophosphamide
followed by docetaxel with the randomized addition of
celecoxib in HER2 negative patients or trastuzumab in
HER2 positive patients [3]. Four centres participated in
this trial and frozen biopsies were mandatory for enrol-
ment. An ancillary study was conducted prospectively in
order to define predictors of response to chemotherapy
The aim of the present study was to present and dis-
cuss the importance of pre-analytical and analytical
steps for transcriptome analysis (using Affymetrix
U133A2) and for RT-qPCR of 45 target genes of interest
in breast cancer in the context of this ancillary study.
Methods
REMAGUS 02 (RO2) study design
This study was conducted from May 2004 to October
2007 as a prospective ancillary study of a multicentre
randomised phase II trial in 340 patients with stage II
and III breast carcinoma, ineligible for breast-conserving
surgery and treated with neoadjuvant chemotherapy
(sequential three-weekly cycles of epirubicin (75 mg/m
2)/
cyclophosphamide (750 mg/m
2) for 4 cycles followed by
docetaxel (100 mg/m
2) for 4 cycles. HER2-negative
patients (n = 220) were randomised to concomitantly
receive docetaxel, celecoxib (800 mg/day) during cycles 5
to 8, or placebo. HER2-positive patients, diagnosed by
IHC and systematically confirmed by FISH analysis (n =
120), were randomised to concomitantly receive doce-
taxel, trastuzumab (8 mg/kg then 6 mg/kg every 3 weeks)
during cycles 5 to 8, or placebo. Details and results of
this trial have been previously published by Pierga et al.
[3]. Four French centres, namely centres 1 to 4, were
involved in this trial. All patients were informed and gave
their signed consent to participate in the trial and the
ancillary studies (French Ethics Committee n°03-55). The
primary objective was pathological complete response
(pCR), evaluated according to Chevalier’s criteria [4].
Secondary objectives were to define genomic profiles of
success (pCR) or failure of each type of treatment.
Tissue samples
Availability of frozen tumour tissues from molecular
studies was mandatory for inclusion in the trial. Breast
biopsies were obtained by a 14-gauge core biopsy device
(centres 1, 2, 3), or surgical biopsy (centre 4) prior to
treatment with one specimen dedicated to standard
pathological diagnosis, and two specimens to RNA
extraction. Fully anonymized biopsy samples were used
in accordance with each institution’s ethical rules.
Tumour biopsies were immediately snap frozen in
RNAse-free conditions and stored at -80°C or in liquid
nitrogen, at local sites. At the end of the trial, they were
shipped in dry ice to the laboratories performing the
various assays.
Tumour cellularity was evaluated on frozen sections of
the biopsies dedicated to RNA extraction by local staff
breast pathologists. Recordings criteria were defined at a
consensus meeting prior to the study. The percentage of
invasive and in situ malignant cells was recorded versus
the amount of benign epithelial cells, stromal cells,
inflammatory cells and necrosis. Semi-quantitative eva-
luation was performed. For patients in whom multiples
biopsies were available, the biopsy with the highest inva-
sive content was used for the analysis. Only samples
containing at least 30% tumour cells were kept for
further analysis.
RNA isolation, quantification and qualification
Total RNA was processed at the end of the trial, in cen-
tres 1, 2 and 3, using a common TRIzol method accord-
ing to the manufacturer’s instructions (Invitrogen
Corporation, Carlsbad, USA) followed by RNA clean-up
using the NucleoSpin RNA II kit (Macherey-Nagel,
Hoerdt, France). In centre 4, total RNA was extracted
prospectively during the trial by using a two-round TRI-
zol method followed by the same clean-up.
T h eq u a n t i t ya n dp u r i t yo fe x t r a c t e dR N Aw e r e
assessed by measuring absorbance at 230, 260 and 280
nm using a NanoDrop ND 1000 spectrophotometer
(Wilmington, USA). Only samples with a 260/280 ratio
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were included in subsequent studies.
Evaluation of RNA integrity was performed using the
Agilent Bioanalyzer 2100 microfluidics-based platform
and the RNA 6000 Nano Lab Chips kit (Agilent, Santa
Clara, CA, USA) in all centres. It was determined by the
combination of the following criteria: 28 s/18 s ratio,
RIN (RNA Integrity Number) and electrophoretic profile
(level of degradation, flat or wavy baseline, DNA con-
tamination, etc.).
Extracted total RNA was submitted to further analysis
if the RIN was greater than 7 and 6 for transcriptome
and RT-qPCR analyses, respectively. Three μgt o t a l
RNA were kept for transcriptome analyses, 1 μg for RT-
qPCR and 500 ng for the FASAY assay to detect p53
mutations (data will be presented in a separate paper).
When an insufficient quantity of RNA material was
available to perform the three analyses, priority was
given to transcriptome analysis. All samples were tested
for albumin DNA contaminants using an intronic albu-
min gene design in qPCR. No amplification of albumin
DNA was observed in our series of samples (Ct > 35).
Total RNA of human breast cancer cell lines T47D and
MDA-MB 231 were used to calibrate reverse transcrip-
tion and standardize real-time PCR.
Transcriptome analysis
Analyses were performed at the Institut Curie Transla-
tional Research Department (Paris). Two micrograms of
total RNA were reverse transcribed into cDNA. After
synthesis of double-stranded cDNA, an in vitro transcrip-
tion reaction was conducted overnight. Resulting ampli-
fied cRNA, labelled by means of biotinylated pseudo-
uridine, was then purified. Experimental replicates
(MAQC A sample, Universal Human Reference RNA,
Stratagene, 740000-41) were included from the first step
in each batch of target preparation to evaluate the repro-
ducibility and batch effect of the whole RNA processing
procedure [5]. In order to monitor the quality of targets
before microarray hybridization, the Institut Curie Affy-
metrix platform established a quality control based on
analysis of the cRNA profile: no more than 40% small
fragments (36-500 nt); more than 20%. long fragments
(> 1500 nt). For samples failing to satisfy these criteria, a
Test3 (GeneChip
®3 Array, Affymetrix) was used and
only high quality cRNA samples from Test3 microarray
assays were processed for human pan-genomic microar-
ray hybridization, i.e. when backgrounds were less than
100 and the housekeeping gene 3’/5’ ratio was less than 3
for GAPDH and less than 6 for b-actin.
Human Genechip U133 plus 2.0 microarray hybridiza-
tion was performed with precisely 10 μgf r a g m e n t e d
cRNA (35-200 nt), overnight at 45°C with shaking. The
detailed protocol can be downloaded from:
http://www.affymetrix.com/support/downloads/manuals/
expression_analysis_technical_manual.pdf. The hybridiza-
tion mix was removed and stored at -80°C, while the
microarray fluorescence was elicited using the Genechip
®
Fluidics Station 450. The hybridized biotinylated-cRNA
signal was amplified by successive reactions with phycoery-
thrin-conjugated streptavidin and biotin. The fluorescence
signal intensity was measured with the GeneChip
® Scan-
ner 3000 (1.56 μm resolution).
Real-time RT-qPCR analysis
Analyses were performed at Institut Curie Molecular
Pharmacology Unit and the Centre René Huguenin
Oncogenetic Laboratory using a common RT-qPCR
procedure.
First-strand cDNA synthesis was performed with 1 μg
total RNA using Superscript II Reverse Transcriptase
(Invitrogen Corporation) in a final volume of 20 μL, as
previously described [6-8]. Quantitative PCR analysis
was performed on 6.25 ng cDNA in duplicate. A 5 μL
diluted sample of cDNA (6.25 ng) was added to 20 μL
of the PCR mix. The thermal cycling conditions com-
prised an initial denaturation step at 95°C for 10 min,
45 cycles at 95°C for 15 sec, and either 60°C or 65°C
depending on the target, for 1 min.
All PCR reactions were performed using the ABI
Prism 7900 Sequence Detection System (Applied Biosys-
tems Inc., Forster City, USA). The PCR Core reagent kit
was used for systems with Taqman probes (Eurogentec,
Liège, Belgium), and the Power SYBR Green PCR mas-
ter Mix (Applied Biosystems Inc.) was used for systems
without Taqman probe. Primers and fluorescent probes
were designed from publisheds e q u e n c e su s i n gP r i m e r
express software (Applied Biosystems Inc.). BLASTN
searches against dbEST and nr (the nonredundant set of
the GenBank sequence database) were performed to
confirm the total gene specificity of the chosen nucleo-
tide sequences and the absence of DNA polymorphisms.
Target sequences were 60-120 long. Forty-five cancer-
related target genes (Additional file 1) involved in the
main signalling pathways associated with in breast can-
cer development were studied (nucleotide and probe
sequences available on request). RPLPO, TATA Box
binding protein (TBP), transferrin receptor (TFR), b-
actin, b-glucuronidase (GUS), and GAPDH were used as
endogenous reference genes. Transferrin receptor-TFRC-
5’ (Hs00951086_m1),G A P D H - 5 ’ (Hs99999905_m1) and
GUSB-3’ (Hs99999908_m1) were obtained as Assays-on-
Demand from Applied Biosystems. Human breast cancer
cell lines T47D and MDA-MB 231 cDNA were used to
generate 8 points standard curves for each gene [6,9].
Target quantities were normalized to each of the refer-
ence genes and to the median of the 6 reference genes
and calibrated using the second point of each standard
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in target gene expression relative to the reference genes
and the calibrator and are expressed as [6]:
Etarget(Ct calibrator − Ct sample)/Ereference gene(Ct calibrator − Ct sample),
w h e r eEi st h ee f f i c i e n c yo fP C Rm e a s u r e du s i n gt h e
slope of the calibration curve, and Ct is the cycle
threshold.
No Reverse-transcription Controls (NTC) were
included in each batch of samples. Only cases with
exploitable data obtained fo rt h e6r e f e r e n c eg e n e sa n d
the 45 target genes were submitted to further statistical
analysis (Additional file 1).
Descriptive analysis and graphical representation RT-
qPCR and transcriptome
We used R software [10] for descriptive analysis and gra-
phical representations. Details on the functions used are
given in Supplementary Methodology (Additional file 2).
In a first step, median estimates [min - max] of
tumour cell percentage, RIN, 260/280 and 28 s/18 s
ratios, and RNA quantities were provided to describe
the distributions of quantitative characteristics of RNA
used for both transcriptome and RT-qPCR analysis.
Comparisons of reference genes Ct means between each
of the four centres were performed using ANOVA
(ANalysis Of VAriance). For each of the 6 reference
genes, a global p-value of Ct mean’s heterogeneity
between all centres was calculated. In order to account
for a possible center effect, a p-value of Ct mean’sh e t -
erogeneity was also provided when excluding one centre
from the ANOVA.
In a second step, a hierarchical clustering on the 239
patients was performed. Spearman correlations of the 45
E
ΔΔCt values between patients (taking each of the six
reference genes or the median of the 6 reference genes
Ct, as the reference gene) were proposed as similarity
measures, and we used a Ward algorithm as the agglom-
erative criterion. Separation into groups was proposed on
the basis of the structure of the dendrogram. Hormonal
receptor status (ER+, PR+), HER2 status (HER2+), Histo-
logical Grade (EE grading system) [11], and the centre
were indicated on the graphic for each patient.
Microarrays data provided by the four centres were
normalized together using the GCRMA procedure [9].
Then, a hierarchical clustering on the 226 patients was
performed. Spearman correlations of the 5000 probe sets
showing the highest values of interquartile range (differ-
ence between the third and first quartiles) were used as
similarity measures, and we used a Ward algorithm as
the agglomerative criterion. Hormonal receptor status
(ER+, PR+), HER2 status (HER2+), Histological Grade,
and the centre were also highlighted for each patient.
Results
Among the 340 pretreatment frozen biopsies, 13 (4%)
initially dedicated to translational studies were used for
diagnosis due to an insufficient quantity of tumour cells
in the diagnostic biopsy and were therefore not
included. Thirty-seven of the 327 biopsies (11%) were
also excluded because they contained less then 30% of
tumour cells. Consequently, 290 biopsies were eligible
for total RNA extraction (Figure 1).
RNA quantification and qualification
According to the qualification criteria defined for each
analysis, 226/290 (78%) samples were available for tran-
scriptome analysis and 239/290 (82%) samples were
available for RT-qPCR. In both cases, we observed that
the proportions of lobular and low grade carcinoma
were significantly higher in excluded material (Addi-
tional file 3 and 4). The median RNA quantity for the 4
centres was 13.21 μg and 12.52 μg for transcriptome
and RT-qPCR series respectively (Table 1 and Table 2).
Median RIN values were equal to 8.40 both for tran-
scriptome and RT-qPCR series (Table 1).
Transcriptome validation criteria
Microarray data are available on GEO with accession
number GSE26639. Here is the link for access:
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
token=lhynjakuucioojq&acc=GSE26639.
Among the 226 patients eligible for transcriptome
analysis, the amplification yields were sufficient to pre-
pare large quantities of cRNA (median: 68 μg) (Addi-
tional file 5). Amplified cRNA, controlled by
electrophoresis, contained a median of 26% of small
fragments and 41% of long fragments. Qualitative analy-
sis of the hybridization signals using MAS5 summariza-
tion algorithm showed that all microarrays had a low
background signal (median: 59.66). For all centres, the
median percentage of present call was 50.04%, and the
GAPDH and b-actin 5’/3’ ratios were similar to those
obtained on Test3 arrays (Additional file 6).
Clustering analysis using the 5,000 most variable
probes highlighted relevant breast cancer phenotypes:
ER+, PR+, HER2+ and triple-negative tumours (Figure 2
andAdditional file 7). A centre effect was also observed,
as illustrated by a cluster defined by patients of centre 4.
Quantitative RT-qPCR validation criteria
Two hundred and thirty nine cases (82%) with adequate
quality and quantity criteria and complete information
for all genes were available for RT-qPCR statistical ana-
lysis. All samples had linear amplification of the TBP
gene from 1/40 to 1/200 dilutions. NTC were greater
than 40 in all cases. No amplification of albumin DNA
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Page 4 of 10Table 1 Quantitative and qualitative characteristics of RNA used for transcriptome analysis: median [min - max]
Characteristics Centre All centres
1234
Tumour
cells (%)
60
[30 - 95]
60
[30 - 90]
50
[30 - 90]
70
[30 - 90]
60
[30 - 95]
RIN 8.40
[6.30 - 9.90]
9.10
[6.90 - 10.00]
8.10
[7.00 - 9.30]
8.30
[6.40 - 9.30]
8.40
[6.30- 10.00]
260/280 ratio 2.08
[1.95 - 2.13]
2.05
[1.72 - 2.17]
2.07
[2.02 - 2.12]
2.09
[1.94 - 2.14]
2.08
[1.72 - 2.17]
28 s/18 s ratio 1.60
[0.70 - 2.10]
1.70
[1.10 - 2.40]
1.40
[1.10 - 1.80]
1.30
[1.00 - 2.00]
1.60
[0.70 - 2.40]
RNA (μg) 16.91
[3.38 - 89.58]
15.98
[2.92 - 64.31]
12.58
[5.00 - 23.00]
6.87
[2.16 - 20.34]
13.21
[2.16 - 89.58]
 
Figure 1 Flow diagram of patients included and frozen tumors of samples available in REMAGUS 02 biological trial (biopsies).
de Cremoux et al. BMC Cancer 2011, 11:215
http://www.biomedcentral.com/1471-2407/11/215
Page 5 of 10was observed. High RT-qPCR efficiencies (> 90%) were
found for each gene transcript. Mean Ct values were
comprised between 20 and 27 for the majority of genes,
and between 31 and 33 for KRT 5, KRT17, PTGS2,
HTER, PROM1 and SERPINB5. Forty-four of the 45
selected genes were considered to be present in all sam-
ples, GSTM1 was undetectable (Ct > 35) in 22% of sam-
ples. Comparison of the mean Ct values of the 6
reference genes in the 239 cases showed that centre 4
exhibited significantly higher Ct values than the other 3
centres. No significant difference was observed between
the 3 remaining centres after excluding centre 4 from
the comparisons. Clustering analysis of the 45 target
gene data obtained in 239 patients and expressed as
E
ΔΔCt related to the median of the 6 references gene
(similar to those expressed as E
ΔΔCt related to each of
t h e6r e f e r e n c eg e n e s ) ,h i g h l i g h t e dE R + ,P R + ,H E R 2+ ,
and triple-negative clusters (Figure 3 andAdditional file
8). No centre effect was demonstrated.
Discussion
This study stressed the importance of pre-analytical
steps and demonstrated the feasibility and reliability of
transcriptome and RT-QPCR analyses in the context of
a randomised multicentre trial of neoadjuvant che-
motherapy in breast cancer. Most published studies
have concerned gene expression analyses in consecutive
series of patients receiving neoadjuvant chemotherapy
[12-15] and for review [16].O n l yaf e wr a n d o m i s e d
trials with gene expression analyses have been con-
ducted in the neoadjuvant setting [17-19]. In this study,
ancillary laboratory studies were shared according to the
Figure 2 Transcriptome analysis: Clustering of 226 patients based on the 5,000 probe sets having the highest Inter-Quartile Range values.
Table 2 Quantitative and qualitative characteristics of RNA used for RT-qPCR analysis: median [min - max]
Characteristics Centre All centres
1234
Tumour
cells (%)
60
[30 - 95]
60
[30 - 90]
50
[30 - 90]
70
[30 - 90]
60
[30 - 95]
RIN 8.40
[6.10 - 9.90]
8.90
[6.70 - 10.0]
8.00
[6.00 - 9.30]
8.30
[6.40 - 9.30]
8.40
[6.00 - 10.00]
260/280 ratio 2.08
[1.99 - 2.13]
2.05
[1.72 - 2.17]
2.08
[2.02 - 2.15]
2.09
[1.94 - 2.14]
2.08
[1.72 - 2.17]
28 s/18 s ratio 1.60
[0.70 - 2.10]
1.70
[1.10 - 2..40]
1.35
[1.00 - 1.80]
1.30
[0.90 - 2.00]
1.60
[0.70 - 2.40]
RNA (μg) 16.77
[2.49 - 89.58]
11.02
[3.15 - 31.95]
13.92
[5.00 - 26.93]
6.90
[3.60 - 20.34]
12.52
[2.49 - 89.58]
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teams participating in the trial. These laboratories have
obtained the “Hospital Molecular Genetics platforms for
cancer” label from the French National Cancer Institute.
Transcriptome analyses were centralised (Institut Curie
translational research department), but RT-qPCR ana-
lyses were performed in two laboratories experienced in
RT-qPCR quality control [6] and who set up common
procedures for this study.
B a s e do no u re x p e r i e n c ea n do np u b l i s h e dd a t a
[20-24], we defined validation criteria for each type of
analysis. Standard operating procedures were devel-
oped by the laboratories by testing selected modifica-
tions of the research protocols to the clinical setting
and by including quality assurance measures. Limits of
acceptability were defined at multiple steps including
histological control of tumour cell percentage, and
specific criteria for microarray and RT-qPCR quality
controls. We used a minimal cutoff of 30% tumor
cells to analyze the samples and we excluded 11%
cases. There is no consensus on the best cut off for
cellularity but our choice was in accordance with two
Table 3 Comparison of mean (standard deviation) Ct of reference genes analyzed by RT-qPCR, for the 4 centres
Reference Gene Centre All centres
1234
TFR 23.85 (0.87) 24.09 (1.28) 24.23 (1.01) 26.30 (1.82) 24.34 (1.47)
b-actin 17.15 (0.58) 17.34 (1.19) 17.10 (0.62) 18.32 (0.88) 17.38 (0.94)
TBP 26.46 (0.53) 26.53 (1.18) 26.81 (0.47) 28.11 (1.10) 26.77 (1.03)
GAPDH 19.78 (0.94) 19.99 (1.27) 19.90 (0.77) 20.47 (1.05) 19.96 (1.07)
RPLPO 19.44 (0.60) 19.43 (1.06) 19.25 (0.78) 20.51 (0.93) 19.59 (0.91)
GUS 22.84 (0.71) 22.98 (1.23) 23.05 (0.76) 24.83 (1.33) 23.21 (1.21)
p-value referring to ANOVA test for each reference gene, when excluding corresponding centre
TFR < 0.001 < 0.001 < 0.001 0.144 < 0.001
b-actin < 0.001 < 0.001 < 0.001 0.256 < 0.001
TBP < 0.001 < 0.001 < 0.001 0.165 < 0.001
GAPDH 0.075 < 0.001 0.003 0.416 0.006
RPLPO < 0.001 < 0.001 < 0.001 0.562 < 0.001
GUS < 0.001 < 0.001 < 0.001 0.457 < 0.001
 
Figure 3 RT-qPCR analysis: Clustering of 239 patients based on the 45 E
ΔΔCt target genes and considering the median Ct of the 6
reference genes as of the reference gene.
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was used in the EORTC 10 994/BIG00-01 trial [16] or
30% in the Mindact trial [25]. While this is not gener-
ally performed, it would be of importance to examine
the tumor characteristics of excluded cases, whatever
the reason (low tumor cell content of unsufficient RNA
quality or quantity) to better analyse potential biais
generated in clinical trials with genomics performed on
frozen samples. We observed in the R02 trial a higher
proportion of lobular and low grade carcinoma in
excluded cases. Around 80% of samples were retained
for transcriptome and RT-qPCR analyses. RIN is gener-
ally considered to be a good tool to evaluate RNA qual-
ity and is used with a cut-off of 7 to select samples
eligible for transcriptome analyses in multicentre clini-
cal trials [25]. We used also additional quality control
criteria (ratio of GAPDH and b-actin 3’ to 5’ probes,
percent background signal, percent call and small and
long cRNA fragment percentages).
Comparison of data from all centres showed that all
transcriptome quality criteria, including RINs, were
identical between centres, except that centre 4 pre-
sented the highest mean percentage of small cRNA
and the lowest percentage of long cRNA. Interestingly,
clustering in the overall population showed the rele-
vant breast carcinoma phenotypes [26], but also
demonstrated a “centre effect”, probably due to the
sampling or extraction methods used in centre 4. A
statistical method described in Johnson et al. [27] was
tested to handle this heterogeneity but this heterogene-
ity still remained. In addition, stability of this centre
effect within clustering representation was also investi-
gated and highlighted a great probability for centre 4
patients to be classified in the same cluster (see Addi-
tional file 2, 7 and 8).
In the present study, RIN appeared to be insufficient
to adequately evaluate the quality of the samples. Sam-
ples with adequate RIN but poor quality cRNA affected
the synthesis of full-length cDNA and hybridization effi-
ciency with an impact on gene expression, as specific
categories of genes may be most affected by RNA qual-
ity [22].
The slightly different RNA extraction method used in
centre 4 probably explained the differences in percen-
tage of small and long cRNA. Handling of biopsies
before freezing may also have been different. This pro-
cedure was optimized before initiation of the trial in
each centre, but minor differences between centres that
are difficult to control may have persisted. This problem
is encountered in all multicentre prospective and retro-
spective, randomised and nonrandomised studies and
should be taken into account when considering the het-
erogeneity of published transcriptome data. Strict
acceptability criteria and quality controls were also
applied to RT-qPCR analyses. The impact of RNA qual-
ity on RT-qPCR analyses was often not investigated in
details in the literature, but the accuracy of gene expres-
sion analyses is clearly highly dependent on RNA quality
[28-31]. A RIN value greater than 5 and a PCR product
length up to 200 bp have been recommended to obtain
reliable RT-qPCR results [29]. We used short PCR pro-
ducts and good quality RNA, as attested by RIN values
above 6. The samples were also checked for the absence
of PCR inhibitors. Moreover, sample-to-sample variation
of PCR efficiency was corrected by using 8 points stan-
dard curves for each gene and each plate. Under these
conditions, quantitative results were obtained for the 45
target genes. Higher Ct values were observed in centre
4, but with no impact on the expected classical breast
cancer clustering. This suggests that the use of short
amplicons and PCR normalization procedures allow
obtaining reproducible RT-qPCR results with poorer
quality RNA samples.
Conclusions
Our data showed that even with strict quality criteria for
RNA integrity assessment we observe a centre effect in the
high throughput expression gene analysis. More stringent
criteria are needed for high throughput analysis for clinical
applications. However, well calibrated and standardized
RT-qPCR allows multicentre analysis of genes transcripts
with high accuracy in the clinical context.
Additional material
Additional file 1: Supplemental Table 1. Details of genes analyzed
by RT-qPCR. This table listed the 45 genes that were analyzed by
RTqPCR. Their symbols and biological pathways are also described.
Additional file 2: Supplemental Methods. Complementary methods
including microarrays data normalization, methods used for clustering
and for the determination of clustering stability are described.
Additional file 3: Supplemental Table 2. Characteristics of available
and excluded material for transcriptome analysis. Clinical and
pathological characteristics of excluded samples for transcriptome
analysis are described. Comparison with the series of included samples is
given (p-values).
Additional file 4: Supplemental Table 3. Characteristics of available
and excluded material for RT-qPCR analysis. Clinical and pathological
characteristics of excluded samples for RT-qPCR analysis are described.
Comparison with the series of included samples is given (p-values).
Additional file 5: Supplemental Table 4. Quantitative and
qualitative characteristics of cRNA for transcriptome analysis
median [min - max]. Median yield of cRNA and median percentage of
small and long cRNA are given for samples of each centre.
Additional file 6: Supplemental Table 5. Quantitative characteristics
of GeneChip Array performance: median [min - max]. Median
background signal, median percentage present calls, median 3’/5’ actin
and GAPDH ratios are given for each centre.
Additional file 7: Supplemental Table 6: Stability results for
clustering performed using transcriptomic data. Stability of the
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Page 8 of 10clustering was assessed using a re-sampling approach as described in
supplemental methods (Additional file 2).
Additional file 8: Supplemental Table 7. Stability results for
clustering performed using RT-qPCR data. Stability of the clustering
was assessed using a re-sampling approach as described in supplemental
methods (Additional file 2).
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